ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
ZEVRA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$10.16+0.22 (+2.21%)
Close on Oct 19, 2026
- Market cap
- $623.18M
- P/E (TTM)
- 10.9
- Dividend yield
- –
ZEVRA THERAPEUTICS, INC. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 21 | TTM Q2 21 | TTM Q1 21 | TTM Q4 20 | TTM Q3 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIPLYFFA | $103.60M | $94.90M | $87.40M | – | – | – | – | – | – | – | – | – | 76.1% | – |
| Consulting Services [Member] | – | – | – | – | – | – | – | $800.00K | $800.00K | $1.80M | $1.70M | $1.30M | – | – |
By region
From the segment and revenue-disaggregation notes of Zevra Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.